title: Hematopoietic recovery after unrelated umbilical cord-blood allogeneic transplantation in adults treated with in vivo stem cell factor (R-MetHuSCF) and filgrastim administration.
abstract: Transplantation with unrelated umbilical cord blood (UCB) is marked by delayed hematologic recovery. This report summarizes two adults with chronic myelogenous leukemia (CML), who received myeloablative conditioning followed by infusion of a non-expanded single UCB graft. These CML patients were enrolled in a clinical trial incorporating concomitant in vivo administration of stem cell factor (R-MetHuSCF) and filgrastim from day of UCB infusion until attained hematopoietic recovery. Each patient engrafted fully with donor UCB, with days to absolute neutrophil count (ANC) >500/microl being 13 and 29 days, respectively. Both patients remain in cytogenetic remission at 28 months follow-up. 'In vivo UCB expansion' with administration of concomitant R-MetHuSCF and filgrastim may facilitate prompt hematologic engraftment.
authors.affiliation: Allogeneic Transplant Program, Case Western Reserve University, Department of Medicine, Ireland Comprehensive Cancer Center, University Hospitals of Cleveland, 11100 Euclid Avenue, Wearn 433, Cleveland, OH 44106-5065, USA.
authors.forename: Punit D
authors.initials: PD
authors.lastname: Wadhwa
authors.forename: Hillard M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: Omer N
authors.initials: ON
authors.lastname: Koc
authors.forename: Jennifer
authors.initials: J
authors.lastname: Jaroscak
authors.forename: David
authors.initials: D
authors.lastname: Woo
authors.forename: Cladd E
authors.initials: CE
authors.lastname: Stevens
authors.forename: Pablo
authors.initials: P
authors.lastname: Rubinstein
authors.forename: Mary J
authors.initials: MJ
authors.lastname: Laughlin
mesh_terms: D000328:Adult; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D004359:Drug Therapy, Combination; D000069585:Filgrastim; D006085:Graft Survival / Q000187:drug effects; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006410:Hematopoiesis / Q000187:drug effects*; D006648:Histocompatibility; D006650:Histocompatibility Testing; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D011994:Recombinant Proteins; D019089:Stem Cell Factor / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous / Q000379:methods; D016896:Treatment Outcome
chemical_list: D019653:Myeloablative Agonists; D011994:Recombinant Proteins; D019089:Stem Cell Factor; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim; C105861:ancestim